Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology

• Published in: Brain (London, England : 1878) Vol. 143; no. 2; pp. 650 - 660
• Main Authors: Blennow, Kaj, Chen, Chun, Cicognola, Claudia, Wildsmith, Kristin R, Manser, Paul T, Bohorquez, Sandra M Sanabria, Zhang, Zhentao, Xie, Boer, Peng, Junmin, Hansson, Oskar, Kvartsberg, Hlin, Portelius, Erik, Zetterberg, Henrik, Lashley, Tammaryn, Brinkmalm, Gunnar, Kerchner, Geoffrey A, Weimer, Robby M, Ye, Keqiang, Höglund, Kina
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01-02-2020
• Subjects: Adult; Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - pathology; Alzheimer’s disease; Amyloid beta-Peptides - cerebrospinal fluid; biomarkers; Biomarkers - cerebrospinal fluid; Clinical Laboratory Medicine; Clinical Medicine; Cohort Studies; CSF; Female; Humans; Klinisk laboratoriemedicin; Klinisk medicin; Longitudinal Studies; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; Neurosciences; Neurovetenskaper; Original; pathology; Peptide Fragments - cerebrospinal fluid; tau; tau Proteins - cerebrospinal fluid; tau; pathology; Alzheimer’s disease; biomarkers; CSF
• ISSN: 0006-8950; 1460-2156; 1460-2156
• DOI: 10.1093/brain/awz346

To date, there is no validated fluid biomarker for tau pathology in Alzheimer's disease, with contradictory results from studies evaluating the correlation between phosphorylated tau in CSF with tau PET imaging. Tau protein is subjected to proteolytic processing into fragments before being secreted to the CSF. A recent study suggested that tau cleavage after amino acid 368 by asparagine endopeptidase (AEP) is upregulated in Alzheimer's disease. We used immunoprecipitation followed by mass spectrometric analyses to evaluate the presence of tau368 species in CSF. A novel Simoa® assay for quantification of tau368 in CSF was developed, while total tau (t-tau) was measured by ELISA and the presence of tau368 in tangles was evaluated using immunohistochemistry. The diagnostic utility of tau368 was first evaluated in a pilot study (Alzheimer's disease = 20, control = 20), then in a second cohort where the IWG-2 biomarker criteria were applied (Alzheimer's disease = 37, control = 45), and finally in a third cohort where the correlation with 18F-GTP1 tau PET was evaluated (Alzheimer's disease = 38, control = 11). The tau368/t-tau ratio was significantly decreased in Alzheimer's disease (P < 0.001) in all cohorts. Immunohistochemical staining demonstrated that tau fragments ending at 368 are present in tangles. There was a strong negative correlation between the CSF tau368/t-tau ratio and 18F-GTP1 retention. Our data suggest that tau368 is a tangle-enriched fragment and that the CSF ratio tau368/t-tau reflects tangle pathology. This novel tau biomarker could be used to improve diagnosis of Alzheimer's disease and to facilitate the development of drug candidates targeting tau pathology. Furthermore, future longitudinal studies will increase our understanding of tau pathophysiology in Alzheimer's disease and other tauopathies.